Graft vs Host Disease Market Epidemiology Report 2025-2035 | Drug Pipeline, Therapies, and Regional Outlook

According to the IMARC Group, the graft vs host disease market size reached a value of USD 1.6 billion in 2024. Looking forward, the 7MM is expected to reach USD 7.3 billion by 2035, exhibiting a growth rate (CAGR) of 14.7% during 2025-2035. This can be attributed to the introduction of innovative drug candidates that aid in overcoming the steroid resistance associated with the disease.

Graft versus host disease (GvHD) refers to a medication condition that can occur after an allogeneic transplant. The graft vs host disease market is experiencing significant growth, primarily driven by the increasing number of hematopoietic stem cell transplantations. This rise is attributed to the escalating prevalence of hematologic cancers and other conditions requiring transplantations. Moreover, advancements in transplant technologies and procedures have improved the overall success rates of transplants, leading to a higher number of patients at risk of graft vs host disease. Additionally, the expanding elderly population, which is highly susceptible to hematologic malignancies and thus may require transplants, contributes to the growth of the graft vs host disease market. 

Furthermore, the elevating awareness among healthcare professionals about graft vs host disease and its treatment options is propelling market expansion. This consciousness about the disease and its medications has led to early diagnosis and improved management of the disease, raising the demand for GvHD therapeutics. Moreover, the growing investment in R&D of novel therapies for GvHD is driving market expansion. Pharmaceutical companies are focusing on developing innovative treatments to address the unmet needs of GvHD patients, further augmenting the market. The graft vs host disease market is expected to experience immense growth with the prevalence of these factors, including stem cell transplantations, advancements in transplant technologies, etc., in the coming years.

Analysis Covered Across Each Country:

• Historical, current, and future epidemiology scenario 

• Historical, current, and future performance of the graft vs host disease market

• Historical, current, and future performance of various therapeutic categories in the market 

• Sales of various drugs across the graft vs host disease market

• Reimbursement scenario in the market 

• In-market and pipeline drugs

Request for a sample of this report: https://www.imarcgroup.com/graft-vs-host-disease-market/requestsample

This report also provides a detailed analysis of the current graft vs host disease market drugs and late-stage pipeline drugs.

In-Market Drugs:

• Drug Overview 

• Mechanism of Action 

• Regulatory Status 

• Clinical Trial Results 

• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

• Drug overview 

• Mechanism of action 

• Regulatory status 

• Clinical trial results 

• Drug uptake and market performance

Competitive Landscape with key players:

The competitive landscape of the graft vs host disease market has been studied in the report with the detailed profiles of the key players operating in the market.

1. Janssen/Pharmacyclics
2. Incyte Corporation/Novartis
3. Bristol-Myers Squibb
4. Kadmon Pharmaceuticals
5. Biocon/Equillium
6. Syndax Pharmaceuticals
7. ASC Therapeutics
8. Incyte Corporation
9. Medac

Countries Covered:

• United States 

• Germany 

• France 

• United Kingdom 

• Italy 

• Spain 

• Japan

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145